Infuseon Therapeutics inked a deal this week with OncoSynergy to evaluate a glioblastoma therapeutic with the Cleveland Clinic spinout’s novel delivery device. The alliance hopes to demonstrate proof-of-concept that OncoSynergy’s candidate can be successfully delivered directly to a patient’s brain using the device in a Phase I glioblastoma trial. Get the full story at our […]
Clinical Trials
Novartis trial results could spell trouble for Regeneron
Head-to-head late-stage clinical trials published on Tuesday showed that a Novartis (NYSE:NVS) drug to treat patients with neovascular age-related macular degeneration doesn’t need to be injected as frequently as a rival drug from competitor Regeneron (NSDQ:REGN). Analysts reportedly said the data gives Novartis’ treatment, RTH258, a competitive edge compared to its rival therapies. Get the full […]
Glaukos touts iStent study with topical travoprost
Glaukos (NYSE:GKOS) touted data today from a 53-patient glaucoma study showing that its iStent device combined with topical travoprost reduced mean intraocular pressure by 35% after 18 months of follow-up. The company’s flagship device is designed to lessen IOP by restoring the natural outflow of aqueous humor through the conventional pathway in a patient’s eye. […]
Rubius snags $120m for red blood cell therapeutics
Rubius Therapeutics, a biotech engineering red blood cells as drug carriers, said today that it raised $120 million in an oversubscribed private financing round. The Cambridge, Mass.-based company plans to use its newly-acquired funds to support its Red-Cell Therapeutics portfolio and prepare for human clinical trials in 2018. Get the full story at our sister […]
Emulate wins $2m NIH grant to study brain-on-a-chip in space
Organ-on-a-chip developer Emulate said today it won a research grant to use its human Brain-Chip system to develop a research platform to be sent to the International Space Station. The company’s Brain-Chip consists of neuronal and vascular endothelial cells in a micro-engineered environment, and experiments will be conducted under healthy and inflamed states to assess […]
Pamplona Capital to acquire Parexel in $5B deal
Parexel said today that it would go private after Pamplona Capital agreed to buy the pharmaceutical research services company in a deal valued at $5 billion. Pamplona is slated to pay $88.10 per share for Parexel, which is a 5% premium to the stock’s close on Monday. Get the full story at our sister site, […]
IsoRay touts another ‘100%’ study
IsoRay (NYSE:ISR) today released data from a study of its Cesium-131 brachytherapy for treating patients with large brain metastases, touting a 100% freedom from local progression. Results from the study were published in the International Journal of Radiation Oncology, Biology, Physics, the Richland, Wash.-based company said. In the study, researchers assessed the impact of low-dose rate […]
Avita Medical touts ReCell skin graft study data
Avita Medical (ASX:AVH) today released data from a trial of its ReCell device used to treat skin graft patients, touting hastened healing and improved final outcomes. The ReCell device is designed to use the patient’s own skin cells to treat a variety of skin issues, including burns, reconstructive and cosmetic procedures, the company said. Results from the […]
InVivo enrolls 16th patient in neuro-spinal scaffold study
InVivo Therapeutics (NSDQ:NVIV) said today it enrolled the 16th patient in the Inspire study of its neuro-spinal scaffold. The Cambridge, Mass.-based company’s neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. The patient was enrolled at Pittsburgh, Penn.’s Allegheny General Hospital after Drs. […]
Medtronic touts cost, treatment data on CRT devices
Medtronic (NYSE:MDT) today touted data showing that a pair of algorithms improved treatment and lowered costs for patients treated with its cardiac resynchronization therapy devices. The Fridley, Minn.-based medical device giant said its AdaptivCRT and EffectiveCRT algorithms lowered costs and improved therapy delivery in heart failure patients with atrial fibrillation. Results from 1 of 3 analyses […]
BioTrace Medical touts real-world data from Tempo temporary lead
BioTrace Medical today released data from real-world experiences with its Tempo temporary pacing lead, touting no dislodgements or perforations and reliable pace capture during and after the procedure. The real-world experiences as well as 2 live cases were presented during the Transcatheter Valve Therapies 2017 in Chicago this week. In a presentation, Dr. Tamim Nazif […]